Minerva Neurosciences (NERV) Cash & Equivalents (2013 - 2026)

Minerva Neurosciences (NERV) has 14 years of Cash & Equivalents data on file, last reported at $32.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 88.89% year-over-year to $32.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.7 million (up 88.89% YoY) and the FY2025 annual result came in at $82.3 million, up 285.27% from the prior year.
• Cash & Equivalents slipped to $32.7 million in Q1 2026, from $82.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $82.3 million in Q4 2025 to a low of $12.3 million in Q3 2025.
• A 5-year average of $36.2 million and a median of $34.6 million in 2022 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 285.27% in 2025, down 53.69% in 2025.
• Tracing NERV's Cash & Equivalents over 5 years: stood at $34.6 million in 2022, then fell by 20.85% to $27.4 million in 2023, then slipped by 21.9% to $21.4 million in 2024, then surged by 285.27% to $82.3 million in 2025, then sank by 60.32% to $32.7 million in 2026.
• The last three Cash & Equivalents figures came in at $32.7 million (Q1 2026), $82.3 million (Q4 2025), and $12.3 million (Q3 2025), per Business Quant data.